Vera Therapeutics Reports Q2 2026 Financial Results

What Happened
Vera Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2026 in a press release dated August 10, 2026. The company furnished that press release as Exhibit 99.1 to a Form 8-K (Item 2.02), reporting its results of operations and providing recent corporate updates. The Form 8-K was signed by Sean Grant, Chief Financial Officer, on August 10, 2026.

Key Details

• Filing: Current Report on Form 8-K filed August 10, 2026 (Items 2.02 and 9.01).
• Reporting period: Quarter ended June 30, 2026.
• Exhibit: Press release furnished as Exhibit 99.1 (not deemed “filed” under Section 18 of the Exchange Act).
• Signature: Report signed by Sean Grant, CFO, dated August 10, 2026.

Why It Matters
This filing notifies investors that Vera has publicly released its quarterly earnings and business updates; investors should read the press release (Exhibit 99.1) for the company’s reported revenue, earnings, guidance, or other material operational information. Note that the press release is furnished (not “filed”), which limits certain legal liabilities under the Exchange Act. For detailed, filed financial statements and more formal disclosures, monitor Vera’s upcoming periodic reports (e.g., 10-Q) and subsequent SEC filings.